Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
This randomized, double-blind, placebo-controlled, multicenter study will evaluate the
effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with
Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 35
days), and a 6-week Treatment Period (during which participants will receive either
NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who
complete the study, provide informed consent, and meet the eligibility criteria may enter an
open-label extension study (NMRA-335140-501).